AUROBINDO PHARMA LTD. - 524804 - Intimation Regarding A Safety Accident On April 6 In Unit 6 Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company.
Intimation regarding a safety accident on April 6, 2024 in Unit 6 of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation of appointment of Mr. T Vijaya Kumar as President, R & D (Specialty Drug Delivery).
Aurobindo Pharma Unit Gets 3 Observations From USFDA After Inspection
Aurobindo Pharma's subsidiary, Eugia Steriles, received three observations from the USFDA after an inspection of its manufacturing unit in Andhra Pradesh. AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At The New Injectable Facility Of Eugia Steriles Private Limited, A 100% Stepdown Subsidiary Of The Company.
Intimation that the USFDA inspected the new injectable facility of Eugia Steriles Limited, a 100% step-down subsidiary of the Company from March 28 to April 5, 2024 and inspection closed with three observations that are procedural in nature. AUROBINDO PHARMA LTD. - 524804 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAUROBINDO PHARMA LTD. 2CIN NO.L24239TG1986PLC015190 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+STABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Baddigam Adi Reddy Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Santhanam Subramanian Designation: Chief Financial Officer EmailId: [email protected] Date: 05/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. AUROBINDO PHARMA LTD. - 524804 - Compliance Certificate For The Year Ended 31.03.2024.
Submission of Compliance Certificate under Regulation 7 (3) Listing Regulations AUROBINDO PHARMA LTD. - 524804 - Compliance Certificate Under Regulation 40(9) For The Year Ended 31.03.2024.
Submission of Compliance Certificate of a Company Secretary in Practice issued under Regulation 40(9) of Listing Regulations for the year ended March 31, 2024 AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of notice published in newspapers about completion of sending Postal Ballot Notice to shareholders of the Company AUROBINDO PHARMA LTD. - 524804 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Submission of Postal Ballot Notice for seeking approval of the shareholders to the appointment of Mr. Mangalam Ramasubramanian Kumar as an Independent Director of the Company AUROBINDO PHARMA LTD. - 524804 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Axis Trustee Services Ltd